Repligen Corporation (RGEN) Expected to Announce Earnings of $0.11 Per Share
Equities analysts expect that Repligen Corporation (NASDAQ:RGEN) will announce $0.11 earnings per share for the current quarter, according to Zacks. Four analysts have issued estimates for Repligen Corporation’s earnings, with estimates ranging from $0.09 to $0.15. Repligen Corporation posted earnings of $0.08 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 37.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Repligen Corporation will report full-year earnings of $0.59 per share for the current year, with EPS estimates ranging from $0.57 to $0.61. For the next year, analysts expect that the company will report earnings of $0.74 per share, with EPS estimates ranging from $0.72 to $0.78. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Repligen Corporation.
Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. During the same period in the previous year, the company posted $0.16 EPS. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year.
RGEN has been the topic of several analyst reports. Janney Montgomery Scott lifted their target price on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. BidaskClub upgraded Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Saturday, August 12th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $40.00 target price on shares of Repligen Corporation in a research report on Thursday, September 14th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Repligen Corporation has an average rating of “Buy” and an average price target of $45.40.
Repligen Corporation (NASDAQ:RGEN) traded up 1.34% during mid-day trading on Friday, hitting $38.43. The company had a trading volume of 178,309 shares. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 75.21 and a beta of 1.18. The firm’s 50 day moving average is $41.40 and its 200 day moving average is $39.66. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. Ameritas Investment Partners Inc. purchased a new position in Repligen Corporation during the first quarter valued at $103,000. Victory Capital Management Inc. lifted its position in Repligen Corporation by 76.6% during the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 1,475 shares in the last quarter. Quantbot Technologies LP purchased a new position in Repligen Corporation during the second quarter valued at $120,000. Oppenheimer Asset Management Inc. purchased a new position in Repligen Corporation during the second quarter valued at $123,000. Finally, JPMorgan Chase & Co. lifted its position in Repligen Corporation by 31.9% during the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 908 shares in the last quarter. Institutional investors own 97.91% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.